Reduced activity of histone deacetylase 2 (HDAC2) has been described in patients with chronic obstructive pulmonary disease (COPD), but the mechanisms resulting in decreased expression of this important epigenetic modifier remain unknown. Here, we employed several in vitro experiments to address the role of microRNAs (miRNAs) on the regulation of HDAC2 in endothelial cells. Manipulation of miRNA levels in human pulmonary artery endothelial cells (HPAEC) was achieved by using electroporation with anti-miRNAs and miRNA mimics. Target prediction software identified miR-223 as a potential repressor of HDAC2. In subsequent stimulation experiments using inflammatory cytokines known to be increased in patients with COPD, miR-223 was found to be significantly induced. Functional analysis demonstrated that overexpression of miR-223 decreased HDAC2 expression and activity in HPAEC. Conversely, HDAC2 expression and activity was preserved in anti-miR-223-treated cells. Direct miRNA-target interaction was confirmed by reporter gene assay. In a next step, reduced expression of HDAC2 was found to increase the levels of the chemokine fractalkine (CX 3 CL1). In vivo studies confirmed elevated expression levels of miR-223 in mice exposed to cigarette smoke and in emphysematous lung tissue from LPStreated mice. Moreover, a significant inverse correlation of miR-223 and HDAC2 expression was found in two independent cohorts of COPD patients. These data emphasize that miR-223, the most prevalent miRNA in COPD, controls expression and activity of HDAC2 in pulmonary cells, which, in turn, might alter the expression profile of chemokines. This pathway provides a novel pathogenic link between dysregulated miRNA expression and epigenetic activity in COPD.
Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by irreversible airflow limitation, chronic inflammation, and emphysematous destruction of the lung tissue. The social and economic burden of COPD is substantial: COPD affects about 10 % of the world's population and, according to prediction models, will become the third leading cause of death by 2020 [1] . The pathogenesis of COPD, however, is incompletely understood. Cigarette smoke and other noxious particles are important risk factors by inducing the release of inflammatory mediators such as tumor necrosis factor (TNF) α [2] , interleukin 1 (IL-1) β [3] , and chemokines [4] . These factors, among other mechanisms, lead to infiltration of the airway epithelium with inflammatory cells, chronic bronchial inflammation, and consecutive tissue destruction [5] .
The expression pattern of major transcription factors downstream of inflammatory cytokines appears to be epigenetically changed. Modifications of histone proteins are -together with DNA methylation -the most important group of epigenetic alterations [6] . Of these, the balance between histone acetylation and deacetylation arguably is the most investigated. Decreased histone deacetylase (HDAC) activity allows the acetylated chromatin to be unbound to histones. In turn, transcription factors can access the chromatin and the mRNA of distinct inflammatory cytokines and chemokines can be produced [7] .
In lung tissue obtained from patients with COPD, the activity of HDAC and especially HDAC2 has been found decreased. Moreover, HDAC2 activity was discovered to be negatively correlated with disease severity [8] . This is an interesting observation with major impact on the pathogenic understanding and novel therapeutic approaches to patients with COPD. To date, however, it remains unclear which mechanisms are responsible for the reduced expression of HDAC2 in COPD.
Of interest, HDAC2 has previously been described to be influenced by micoRNAs (miRNAs) in liver cancer [9] . miRNAs are endogenously expressed small noncoding RNA molecules of [20] [21] [22] nt that bind to complementary sequences within the 3′-untranslated region (UTR) of target mRNAs in order to repress their expression [10] . It is assumed that more than 60 % of the human genome is regulated by miRNAs [11] .
Conversely, the role of miRNAs in the pathogenesis of COPD is only poorly understood, and the potential impact of miRNAs on the expression of HDAC2, a key player in the pathogenesis of COPD [8] , and on the inflammatory response in human pulmonary cells remains unknown.
The present study was designed to test the hypothesis that HDAC2 is regulated via miRNA and the potential of these miRNAs to maintain a chronic inflammatory response in COPD.
Material and methods

Human patient samples
Lung tissue samples from COPD patients were obtained through our tissue bank in collaboration with the Division of Thoracic Surgery at the University Hospital of Zurich. In the present study, patients with severe COPD that fulfilled the Global Initiative for COPD (GOLD) criteria were included. Written informed consent was obtained from all patients. The study design was approved by Zurich's ethical review committee (KEK ZH-no. 2014-0011). Validation of human gene expression was performed in patient samples derived from the GLUCOLD study cohort measured by Affymetrix Human Gene ST array and Affymetrix miRNA 2.0 array (GSE36221) [12] [13] [14] .
Cell culture
Human hepatocellular carcinoma (HepG2) cells were grown in Dulbecco's modified Eagle's medium supplemented with 10 % fetal bovine serum, 1 % penicillin-streptomycin, and 1 % HEPES. The HepG2 cell line was provided by the Department of Clinical Pharmacology and Toxicology of the University Hospital Zurich [15] . Human pulmonary artery endothelial cells (HPAEC, from Gibco, Life Technologies, Zug, Switzerland), human pulmonary artery smooth muscle cells (HPASMC, from Gibco), normal human bronchial epithelial cells (NHBEC from Lonza, Basel, Switzerland), and monocytes (Mono-Mac-6 cells from DSMZ, Braunschweig, Germany) were cultured according to the manufacturer's instruction. All cells were incubated at 37°C in 5 % CO 2 atmosphere. When reaching 80 % confluency, adherent cells were trypsinized in trypsin-EDTA and prepared for experiments. In all experiments performed, cells from passage 5-9 were used. Cells were seeded and allowed to settle for at least 24 h before being transfected or stimulated. Cultured cells were stimulated either with IL-1β, TNF-α, or a cocktail of both with a concentration of 10 ng/ml, respectively. All stimulation agents are purchased from Sigma-Aldrich (Buchs, Switzerland). Stimulation was performed over different time points (24, 48 , or 72 h).
Experimental in vivo models
To induce lung emphysema and COPD in an animal model, mice were exposed to cigarette smoke from research cigarettes (1R4F, University of Kentucky, USA) for 5 days per week as described elsewhere [16] . After 3 weeks, mice were euthanized and total RNA including miRNAs from lung tissue was isolated. In the second model, mice were treated either with lipopolysaccharide (LPS) or with control phosphatebuffered saline (PBS) inhalants as described before to induce elastase which leads to the development of lung emphysema [17] . Paraffin-embedded mouse lung tissue samples were used for quantification of miRNAs. Both animal models were provided by our collaborators Benjamin Marsland and Giovanni Camici. The animal experimentation was approved by the local Canton's Veterinary office.
Molecular biology methods
A detailed description of several molecular biology methods including plasmid construction, reporter gene assay, transfection, RNA isolation from tissue, cultured cells, supernatants, and paraffin blocks, quantification of gene expression and mature miRNAs, Western blot, and HDAC/ HDAC2 Glo assay can be found in the Electronic Supplementary Material of this article.
Data processing
All data are presented as the mean ± standard deviation (SD) of the indicated number of observations. Parametric or nonparametric distribution of data was determined using the Kolmogorov-Smirnov test. The paired or unpaired t test (two-tailed) as a parametric method for testing was applied. Correlation analysis of normal distributed data was carried out using Pearson's one-tailed correlation test reflecting the inverse relation of the expression of miRNAs and their associated targets. A p value <0.05 was considered to be statistically significant (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001). Statistical evaluations were performed with the software package GraphPad Prism Version 5.0a (GraphPad Software, La Jolla, CA, USA).
Results
miR-223 directly targets HDAC2
To address the question whether the observed reduction of HDAC2 protein in COPD patients could be mediated by the action of miRNAs, DICER1, a key protein in miRNA processing, was silenced in HPAEC using siRNA directed against DICER1. As shown in Fig. 1 , levels of DICER1 mRNA were Fig. 1c ). These data indicate a negative correlation between the expression levels of HDAC2 and DICER1 implying a potential miRNA-mediated mechanism of HDAC2 regulation in HPAEC.
To determine which miRNA could be involved in HDAC2 repression, the following strategy was applied: (i) search for HDAC2-targeting miRNAs using computational algorithms [18] and (ii) focus on miRNAs previously associated with COPD. Based on this strategy, three miRNAs were selected for further experiments: miR-182, miR-223, and, as a positive control, miR-145 that has been recently shown to target HDAC2 [9] .
Next, a luciferase reporter gene assay was used to investigate whether selected miRNAs directly interact with HDAC2. Reporter gene assay was carried out in HepG2 cells since these cells show high transfection efficacy. In addition, the interaction of miR-145 with HDAC2 was reported in HepG2 cells [9] . After transfection of luciferase constructs comprising the entire 3′-UTR of HDAC2 and co-transfection of mimics of miR-145, miR-182, and miR-223, luciferase activity was measured. As presented in Fig. 2a , miR-145 significantly decreased luciferase activity of the construct encoding part 2 of HDAC2 (reduction to 0.77 ± 0.18, p = 0.046) whereas miR-223 significantly repressed the activity of the construct encoding part 2 (reduction to 0.7 ± 0.11, p = 0.004) and part 3 (reduction to 0.76 ± 0.14, p = 0.042). In contrast, miR-182 failed to decrease luciferase activity of any of the used constructs. These data indicate that the 3′-UTR of HDAC2 contains functional seed matches of miR-223.
Inflammatory cytokines induce the levels of miR-223
To further investigate the role of miR-223 in COPD, the levels of miR-223 were quantified in pulmonary cells. As shown in Fig. 3a , miR-223 levels could be measured and detected in HPASMC, NHBEC, and HPAEC. Next, stimulation experiments were performed using cytokines that have been shown to be highly upregulated in COPD: IL-1β and TNFα [2, 3] . As demonstrated in Next, the effect of cytokine stimulation on miR-223 levels was tested in other pulmonary cells and in monocytes. As shown in Fig. 4a , b, stimulation of NHBEC and HPASMC with a cocktail of IL-1β and TNFα had no significant effect on miR-223 levels. The expression of miR-223 was significantly reduced in cell extracts of monocytes stimulated for 72 h (reduction to 0.47 ± 0.06, p < 0.001, Fig. 4c ). Conversely, levels of miR-223 in the supernatants were found significantly increased (72 h of stimulation, 1.7 ± 0.46-fold, p = 0.027, Fig. 4d ).
These data demonstrate an endothelial cell-specific cytokine-induced effect on miR-223 expression and, moreover, indicate that after cytokine treatment monocytes might release miR-223 in the extracellular space.
miR-223 targets HDAC2 in HPAEC
In a next step, we addressed the question whether miR-223 affects HDAC2 activity in HPAEC. After transfection with mimic or inhibitor of miR-223, HDAC2 activity was measured using a total HDAC or a specific HDAC2 activity assay. Enforced expression of miR-223 resulted in a significant decrease of total HDAC (reduction to 0.73 ± 0.15, p = 0.007) and HDAC2 activity (reduction to 0.69 ± 0.18, p = 0.007) as compared to scrambled transfected control cells (Fig. 5a, b) . Conversely, miR-223 inhibition led to increased total HDAC and HDAC2 activity, however, without reaching statistical significance (Fig. 5a, b) .
Regarding the expression of HDAC2, the same samples were analyzed for mRNA and protein levels of HDAC2. Transfection of HPAEC with miR-223 decreased the mRNA levels of HDAC2 to 0.86 ± 0.15 (p = 0.099) whereas miR-223 inhibition significantly increased mRNA levels of HDAC2 by 1.08 ± 0.036-fold (p = 0.007) as compared to control cells (Fig. 5c, d) . When protein levels of HDAC2 were analyzed, a significant decrease of HDAC2 protein levels in miR-223 mimic-transfected HPAEC was observed (reduction of 31 ± 19 %; p = 0.021, Fig. 5e ). However, treatment with miR-223 inhibitor did not significantly influence the protein levels of HDAC2 (Fig. 5e) .
miR-223 induces the expression of fractalkine via HDAC2
To investigate the downstream effect of decreased HDAC2 activity, the mRNA levels of fractalkine (CX 3 CL1), a chemokine expressed in the endothelium, was assessed. As presented in Fig. 6 , a tendency to an increased expression of CX 3 CL1 in HPAEC transfected with miR-223 mimic was observed (Fig. 6a) . Similarly, treatment with anti-miR-223 led to a reduction of the mRNA level of CX 3 CL1 (Fig. 6b) .
The role of miR-223 in vivo
To confirm a dysregulated expression of miR-223 and its target HDAC2 in vivo, levels of miR-223 were measured in two experimental models of lung emphysema and COPD. First, mice were treated with LPS to induce lung inflammation and lung dysfunction [17] , and the levels of miR-223 in lung tissue were found significantly upregulated as compared to salinetreated control mice (fold change of 1.97 ± 0.12, p = 0.006, Fig. 7a ). These data were confirmed in a small number of cigarette smoke-exposed mice showing increased levels of miR-223 (fold change of 1.63 ± 0.62, n = 3, Fig. 7b ). Moreover, human lung tissue from COPD patients was analyzed for miR-223 and HDAC2 expression. As presented in Fig. 7c , a negative correlation between the expression of HDAC2 and the levels of miR-223 was found in patients with severe COPD (r = −0.532, p = 0.046, n = 11) collected in our own tissue bank at the University Hospital Zurich. Similar results were obtained by analyzing patient samples from the databank of the GLUCOLD study [12] confirming a negative correlation between miR-223 and its target HDAC2 (r = −0.224, p = 0.047, n = 57, Fig. 7d ).
Discussion
In this study, we provide evidence of a novel role for miR-223 in the pathogenesis of COPD. In detail, we show that (i) HDAC2 is directly targeted by miR-223 through binding to seed matches located in the 3′-UTR of its mRNA transcript, (ii) total HDAC and HDAC2 activity is repressed in pulmonary endothelial cells in response to miR-223 overexpression, (iii) inflammatory cytokines known to be upregulated in COPD patients significantly induce the levels of miR-223 in endothelial cells, (iv) miR-223 is upregulated in experimental models of the disease, and (v) the levels of miR-223 negatively correlate with the expression of HDAC2 in human lung tissue from COPD patients. These data further indicate that exposure to inflammation increases the levels of miR-223 in the lung endothelium, which, through repression of HDAC2 and release of chemokines, might provide a positive inflammatory feedback loop in the pathogenesis of COPD. Taken together, our findings offer a novel mechanistic explanation for the previously described downregulation of HDAC2 in patients with COPD [8] .
The expression and activity of HDAC2 was previously shown to be repressed in COPD patients and, as such, was found to be linked to disease severity [8] . While previous studies reported that nitration of tyrosine residues affect activity and stability of HDAC2 protein [19] and, moreover, that proteosomal imbalance might be of critical importance for these processes [20] , the regulation of HDAC2 gene context of COPD, miR-223 was recently described as the most upregulated miRNA in lung tissue of patients, but its function has not been addressed [21] . Several miRNA target prediction algorithms identified potential binding sites of miRNAs that included seed matches for miR-223 in the 3′-UTR of HDAC2 [18] . Moreover, the interaction of miRNAs with HDAC2 has previously been described in liver cancer where miR-145 was reported to act as tumor suppressor by targeting HDAC2 [9] . Due to these facts, the direct interaction of different miRNAs expressed in pulmonary cells and predicted to bind to the 3′-UTR of HDAC2 was investigated. Subsequent reporter gene analysis confirmed the interaction of miR-145 and, as a novel finding, of miR-223 with the 3′-UTR of HDAC2. We further identified seed matches located in the last two parts of the 3′-UTR of HDAC2 indicating that these binding sites are targeted by miR-223. These results supported our hypothesis of a posttranscriptional regulation of HDAC2 by miR-223. In functional studies, we demonstrated that enforced expression of miR-223 in pulmonary endothelial cells leads to a significant reduction of protein levels and activity of HDAC2 in these cells. The mRNA levels, however, remained almost unchanged suggesting a miRNA-mediated inhibition of the translational process of the targeted transcript. Such a mechanistic interplay is frequently observed in the context of miRNA-mediated gene regulation in human disease including pulmonary disorders [22] . Of note, when miR-223 was silenced using miRNA inhibitors, only minor effects could be observed on the expression levels of HDAC2. This finding might be explained as a consequence of the low basal expression levels of miR-223 in unstimulated pulmonary endothelial cells derived from healthy donors, in which no additional suppression can be achieved by the antagonization of miR-223.
Chronic inflammation in COPD is orchestrated by the activity of cytokines and chemokines, of which many can be detected at increased levels in the circulation of patients [5, 23] . In stimulation experiments using endothelial cells that, in vivo, reflect the first responders of the lungs to these proinflammatory signals, we found that IL-1β and TNFα significantly induced the levels of miR-223 in a time-dependent manner. These cytokines have been described as key inflammatory mediators in COPD [2, 3] , and their activity in COPD patients might explain the significant upregulation of miR-223 levels in vivo as shown by Ezzie and colleagues [21] . Both cytokines are activators of the transcription factor nuclear factor kappa B (NF-κB). This signaling pathway has previously been proposed as link between cigarette smoke-induced inflammation, cytokine release, and histone acetylation [24] . Our data support this notion (Fig. 8 ), but at this moment it remains unclear whether the cytokine-triggered induction of miR-223 is a downstream event Fig. 7 miR-223 expression in vivo. a miRNAs were isolated from paraffin-embedded lung tissue specimen of mice that have been treated with lipopolysaccharide (LPS) to induce chronic obstructive pulmonary disease (COPD). Analysis by qPCR showed that the expression levels of miR-223 were significantly upregulated in LPS-treated mice as compared to saline-treated control mice (n = 5). b miRNAs were isolated from fresh total lung tissue of mice exposed to cigarette smoke. Analysis by qPCR demonstrated an increase in miR-223 levels in mice exposed to cigarette smoke compared to control mice (n = 3). c Linear regression shows a significant negative correlation between HDAC2 and miR-223 expression levels in total lung tissue from COPD patients conducted by University Hospital Zurich (n = 11). d These findings are confirmed in a COPD patient cohort from the University of Groningen (n = 57). Statistical analysis by unpaired Student's t test (**p < 0.01) and linear regression by Pearson one-tailed correlation test in a 95 % confidence interval (p < 0.05) of the NF-κB signaling or, alternatively, acts as an independent factor.
As a consequence of our stimulation experiments showing that miR-223 is most inducible in endothelial cells and the fact that these cells might act as pulmonary gatekeeper for inflammatory cells and cytokines and, as such, provide the interface between lung tissue and blood circulation, the focus of this study was set on HPAEC. Endothelial cells secrete chemoattractants (e.g., CX 3 CL1) and might control inflammation within the lung tissue. The interaction between monocytes and endothelial cells is further highlighted by the fact that, upon stimulation with inflammatory cytokines, miR-223 is released from monocytes. Such a mechanism might indicate exosomal transfer of miR-223 to endothelial cells as suggested previously [25] and, potentially, to other lung cells. Moreover, HPAEC are of further interest since endothelial dysfunction in smokers is well recognized [26, 27] and might contribute to altered inflammatory signaling. Since no effect on the expression levels of miR-223 has been observed in stimulation experiments using smooth muscle and bronchial epithelial cells, a cell type-specific effect of miR-223 induction upon cytokine stimulation cannot be excluded. As such, it remains elusive at the moment whether these mechanisms apply also to alveolar macrophages, in which reduced HDAC2 activity has initially been described [8] .
As functional readout downstream of reduced HDAC2 activity, we observed an increase of CX 3 CL1 (fractalkine) in HDAC2-deficient endothelial cells. Fractalkine is an important chemokine with a well-established role in the context of COPD and cigarette smoke-induced inflammation [4, 28] . As membrane-anchored protein, fractalkine acts as an adhesion molecule on the surface of the endothelium, while its soluble form attracts inflammatory cells along a chemical gradient [29] . Here, we identified a regulatory pathway in pulmonary endothelial cells involving inflammatory cytokines, miRNAs, and HDAC2 that result in increased expression of fractalkine (Fig. 8) . Our data show that stimulation of HPAEC with IL-1β and TNFα increases the expression levels of miR-223. The association between chronic inflammation and increased miR-223 levels was further emphasized in experimental models of COPD in which mice either treated with LPS or exposed to cigarette smoke showed elevated levels of miR-223 in their lungs when compared to control mice. Increased levels of miR-223 were further found to reduce both expression and activity of HDAC2 in vitro. Of note, a negative correlation of miR-223 levels with HDAC2 expression was found in lung specimens of COPD patients from two independent tissue banks. According to Ito and colleagues, less HDAC2 activity contributes to inflammatory processes in lung disease [8] . These results were confirmed here by showing the upregulation of fractalkine following transfection of miR-223 mimics. This is a novel observation and highlights the importance of epigenetic modulation in the progression of COPD, which, as indicated by these experiments, might be mediated by the action of miRNAs [30] .
Conclusion
To the best of our knowledge, this is the first report that has characterized the underlying mechanisms of noncoding RNAs involved in decreased HDAC2 activity in COPD patients. We provide evidence that one of the most prevalent miRNA in lung tissue (i.e., miR-223) directly targets HDAC2. Reduced HDAC2 activity, in turn, induces the expression of fractalkine. Whether miR-223 can be used as a novel drug target in the treatment of lung inflammation in the context of COPD has to be addressed by further studies. 
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Pulmonary Endothelial Cells Fig. 8 Proposed regulatory mechanism of miR-223 in COPD. The main components of a novel regulatory pathway in pulmonary arterial endothelial cells involve the action of inflammatory cytokines, miRNAs, and HDAC2. Direct silencing of HDAC2 by miR-223 result in increased expression of the chemokine fractalkine that, in turn, might adhere more monocytes to the endothelium
